Daewoong Pharmaceutical said on the 9th that operating profit on a consolidation basis last year was 196.8 billion won, up 33.0% from a year earlier. Sales in the same period rose 10.4% to 1.5709 trillion won.
The key driver of the improved results is cited as the expansion of overseas exports of flagship products. Leading with the botulinum toxin "Nabota," the company has been steadily lifting its share in the United States, the world's largest market. In the United States, it is sold under the product name "Jeuveau" and currently ranks second with a 14% market share. Daewoong Pharmaceutical is also accelerating its push into the Latin American market, including signing an export contract for Nabota with Mexico on the 8th.
Growth of in-house developed new drugs also supported the results. Representative examples are the potassium-competitive acid blocker (P-CAB) class gastroesophageal reflux disease treatment "Fexuclue" and the diabetes treatment "Envlo."
Fexuclue won marketing approval in China last year. It is expected to quickly expand market share locally by highlighting improvements over proton pump inhibitor (PPI) treatments, which have been criticized for slow onset of action and a short half-life.
Envlo is also stepping up its global expansion. Following marketing approval in Indonesia last year, it has signed export contracts with eight Latin American countries, widening its reach into Southeast Asia and Latin America.
A Daewoong Pharmaceutical official said, "Operating profit improved significantly thanks to increased sales of in-house new drugs and expanded exports of high-margin products."
Meanwhile, Daewoong, the holding company of Daewoong Group, saw sales on a consolidation basis rise 6.8% year over year to 2.0686 trillion won in 2025. Operating profit, however, fell 7.0% to 262.05 billion won from a year earlier. Net profit for the period surged 222.9% to 222.37 billion won.